Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Autogene Cevumeran · RO7198457, BNT-122

Vaccine (mRNA vaccine) · Immune activation, directed at patient-specific tumor-associated antigens · developed by BioNTech

Phase 2 Most advanced trial
BNTX Developer
2 Registered trials

What is Autogene Cevumeran?

Autogene cevumeran is an individualized mRNA-based therapeutic cancer vaccine encoding tumor-associated antigens specific to each patient's cancer. Antigen-presenting cells take up and translate the mRNA, presenting the antigens on MHC molecules to induce cytotoxic T-lymphocyte and memory T-cell responses. It is studied in colorectal cancer (stage II and III) and pancreatic ductal adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RO7198457, BNT-122, RG 6180
Drug type
Vaccine (mRNA vaccine)
Targets
patient-specific tumor-associated antigens (antigen)
Mechanism
Immune activation, directed at patient-specific tumor-associated antigens
Pathways
MHC presentation of antigens by antigen presenting cells, cytotoxic T-lymphocyte and memory T-cell responses
Therapy area
Oncology
Developer
BioNTech SE (BNTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
L8HDH9IB06

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05968326 Phase 2 Adenocarcinoma, Pancreatic Ductal Active not recruiting BNTX
NCT04486378 Phase 2 Colorectal Cancer Stage II Active not recruiting BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adenocarcinoma, Pancreatic DuctalColorectal Cancer Stage IIColorectal Cancer Stage III

More from BioNTech

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the BNTX page.

Follow BNTX, the company behind Autogene Cevumeran

See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BNTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.